Neuronetics Announced as Winner by 2022 Merit Awards for Technology

Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) has been awarded the 2022 bronze medal in the HealthTech category by the Merit Awards for its NeuroStar Advanced Therapy, a notable innovation in mental health treatment.

NeuroStar offers a non-drug solution for psychiatric disorders, particularly depression. Over 4.8 million treatments have been delivered, supported by extensive clinical data. CEO Keith J. Sullivan emphasized the company's commitment to improving patient lives and continuing innovation in neurohealth.

Positive

• Awarded 2022 bronze in HealthTech category by Merit Awards for NeuroStar technology.
• NeuroStar therapy recognized for innovation in treating psychiatric disorders, including depression.
• Over 4.8 million NeuroStar treatments delivered, indicating strong market acceptance.

Negative

• None.

NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health

MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named a 2022 bronze winner by the Merit Awards for Technology in the HealthTech category for its NeuroStar Advanced Therapy.

“It is an incredible feeling to win an award where our NeuroStar technology is recognized for its innovation and ability to help thousands of people living with psychiatric disorders such as depression,” stated Keith J. Sullivan, President, and CEO of Neuronetics Inc. “Thank you to the Merit Awards team for this significant recognition. We will continue to innovate as we strive to fulfill our mission of transforming neurohealth and helping as many people as possible.”

Merit Awards is an independent awards program that acknowledges global companies that are shaping today’s world and their contributions to the market they serve. The judges base their decision on the technology's innovation and how it can help consumers nationwide.

“Our amazing team of judges chose Neuronetics as a bronze winner in the HealthTech category because their NeuroStar technology serves a critical need for those struggling with their mental health,” said Marie Zander, Executive Director of Merit Awards. “We believe Neuronetics’ technology is meeting the need by providing an excellent non-drug treatment solution.”

To access the full list of winners, visit Merit-Awards.com. For more information about NeuroStar, please visit NeuroStar.com.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

FAQ

What is the significance of Neuronetics winning the Merit Award in 2022?

Neuronetics won the bronze medal in the HealthTech category for its NeuroStar Advanced Therapy, recognizing its innovation in mental health treatment.

How many treatments has NeuroStar delivered?

NeuroStar has delivered over 4.8 million treatments, indicating its widespread use and acceptance.

What conditions does NeuroStar Advanced Therapy address?

NeuroStar is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and to alleviate anxiety symptoms in adults.

Who is the CEO of Neuronetics?

Keith J. Sullivan is the President and CEO of Neuronetics, emphasizing the company's mission in neurohealth.

Where can I find more information about NeuroStar?

More information about NeuroStar can be found on their official website at NeuroStar.com.